San Diego, USA – The Department of Health – Abu Dhabi and Boehringer Ingelheim, one of the world’s leading biopharmaceutical developers, have signed a strategic cooperation agreement to leverage Abu Dhabi’s advanced genomics ecosystem. This supports the future of precision medicine in the UAE and contributes to advanced scientific insights into the genetic factors that cause diseases.
The memorandum of understanding was signed during the Biotechnology Innovation Organization’s 2026 World Conference, which was held in San Diego, USA.
The partnership focuses on cardiovascular diseases, diabetes, oncology, rare diseases, neurological disorders, and metabolic diseases. Fibrous diseases, ophthalmology, and conditions related to the immune system. In addition to exploring opportunities to develop research information on genetic and population-related factors influencing disease development and response to treatments. Which enhances the progress of precision medicine in the Emirates.
A leading global system
Dr. Asma Al Mannai, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi, confirmed that Abu Dhabi has succeeded in establishing a leading global system for genomics and population health research.
She pointed out that the cooperation embodies the department’s commitment to harnessing these capabilities to deepen understanding of the factors that develop diseases and respond to treatments among community members. To support future research, develop personalized health methodologies, and lead to more efficient and sustainable health outcomes for Abu Dhabi and the region.
Enhancing collaboration and data integration
For his part, Osama Al-Hajj, General Manager and Head of the Human Medicines Sector in the Near East and the UAE at Boehringer Ingelheim, stressed that accelerating scientific achievements is linked to enhancing cooperation and integrating data and research.
He pointed out that Abu Dhabi’s strategic investments in the pillars of precision medicine, from genomics programs and research infrastructure to the national vision, have consolidated its leadership in the future of healthcare.
He added that the partnership reflects a shared commitment to understanding the spread of diseases and addressing unmet medical needs. Supporting research to achieve more accurate health outcomes that benefit patients. Mapping a future driven by innovation, science, and effective partnerships to improve the health of future generations.
